Production (Stage)
Cadrenal Therapeutics, Inc.
CVKD
$13.70
-$0.16-1.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.88M | 6.75M | 4.92M | 4.14M | 3.71M |
| Depreciation & Amortization | 6.80K | 1.90K | 2.10K | 2.30K | 2.40K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.13M | 10.96M | 7.95M | 6.63M | 5.19M |
| Operating Income | -13.13M | -10.96M | -7.95M | -6.63M | -5.19M |
| Income Before Tax | -12.83M | -10.65M | -7.61M | -6.24M | -4.85M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.83 | -10.65 | -7.61 | -6.24 | -4.85 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.83M | -10.65M | -7.61M | -6.24M | -4.85M |
| EBIT | -13.13M | -10.96M | -7.95M | -6.63M | -5.19M |
| EBITDA | -13.13M | -10.96M | -7.94M | -6.63M | -5.19M |
| EPS Basic | -9.06 | -8.54 | -7.05 | -5.88 | -4.92 |
| Normalized Basic EPS | -5.66 | -5.33 | -4.41 | -3.68 | -3.08 |
| EPS Diluted | -9.06 | -8.54 | -7.05 | -5.88 | -4.92 |
| Normalized Diluted EPS | -5.66 | -5.33 | -4.41 | -3.68 | -3.08 |
| Average Basic Shares Outstanding | 5.66M | 4.88M | 4.31M | 4.23M | 3.94M |
| Average Diluted Shares Outstanding | 5.66M | 4.88M | 4.31M | 4.23M | 3.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |